What do systematic reviews say?

Specially processed cereals vs placebo

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Specially processed cereals vs placebo

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Specially processed cereals vs placebo

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

PUFA vs monounsaturated fatty acid (MUFA)

It is very uncertain whether polyunsaturated fatty acid (PUFA) changes relapse(assessed as number of participants experiencing relapse) compared with monounsaturated fatty acid (MUFA) (very low certainty).

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  RR 1.02 [0.88, 1.2]
  3 studies · 217 participants
  Very low

Omega‐3 vs omega‐6

Omega‐3 showed no clear difference in SAEs (assessed as number of participants experiencing a SAE) compared with omega‐6 (low certainty).

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  RR 1.12 [0.38, 3.31]
  4 studies · 230 participants
  Low

Antioxidants vs placebo

Antioxidant showed no clear difference in relapse(assessed as number of participants experiencing relapse) compared with placebo (low certainty).

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  RR 0.98 [0.59, 1.64]
  4 studies · 345 participants
  Low

Antioxidants vs placebo

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 490 participants
  Very low

Antioxidants vs placebo

Antioxidant showed no clear difference in global impression of deterioration (investigator defined global… compared with placebo (low certainty).

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  RR 0.99 [0.5, 1.93]
  2 studies · 190 participants
  Low

Antioxidants vs placebo

It is very uncertain whether antioxidant changes MRI activity(assessed as number of participants with… compared with placebo (very low certainty).

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  RR 0.67 [0.09, 4.88]
  2 studies · 131 participants
  Very low

Antioxidants vs placebo

Antioxidant showed no clear difference in SAEs (assessed as number of participants experiencing a SAE) compared with placebo (low certainty).

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  RR 0.72 [0.17, 3.08]
  3 studies · 222 participants
  Low

PUFA vs monounsaturated fatty acid (MUFA)

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 102 participants
  Very low

PUFA vs monounsaturated fatty acid (MUFA)

Polyunsaturated fatty acid (PUFA) showed no clear difference in global impression of deterioration (investigator defined global… compared with monounsaturated fatty acid (MUFA) (low certainty).

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  RR 0.85 [0.71, 1.03]
  4 studies · 542 participants
  Low

PUFA vs monounsaturated fatty acid (MUFA)

The review found no eligible studies for this question.

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

PUFA vs monounsaturated fatty acid (MUFA)

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Low

Omega‐3 vs omega‐6

Omega‐3 showed no clear difference in relapse(assessed as number of participants experiencing relapse) compared with omega‐6 (low certainty).

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  RR 1.02 [0.62, 1.66]
  2 studies · 129 participants
  Low

Omega‐3 vs omega‐6

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 166 participants
  Low

Omega‐3 vs omega‐6

Omega‐3 showed no clear difference in global impression of deterioration (investigator defined global… compared with omega‐6 (moderate certainty).

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  RR 0.99 [0.51, 1.91]
  1 study · 86 participants
  Moderate

Omega‐3 vs omega‐6

• Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 86 participants
  Moderate

Intervention not reported

• Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  24 studies · 2785 participants
  Low

Intervention not reported

The intervention showed no clear difference in adverse events (serious adverse events) (low certainty).

• Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age… 2017 · Cochrane Headline outcomes only
  RR 0.57 [0.17, 1.93]
  31 studies · 4096 participants
  Low